Your browser doesn't support javascript.
Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
Ekins, Sean; Mottin, Melina; Ramos, Paulo R P S; Sousa, Bruna K P; Neves, Bruno Junior; Foil, Daniel H; Zorn, Kimberley M; Braga, Rodolpho C; Coffee, Megan; Southan, Christopher; Puhl, Ana C; Andrade, Carolina Horta.
  • Ekins S; Collaborations Pharmaceuticals, 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA. Electronic address: sean@collaborationspharma.com.
  • Mottin M; LabMol - Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil.
  • Ramos PRPS; LabMol - Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil.
  • Sousa BKP; LabMol - Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil.
  • Neves BJ; LabMol - Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil.
  • Foil DH; Collaborations Pharmaceuticals, 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
  • Zorn KM; Collaborations Pharmaceuticals, 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
  • Braga RC; InsilicAll, São Paulo, SP 04363-090, Brazil.
  • Coffee M; Division of Infectious Diseases and Immunology, Department of Medicine, New York University, NY, USA; Department of Population and Family Health, Mailman School of Public Health, Columbia University, NY, USA.
  • Southan C; TW2Informatics Ltd, Göteborg 42166, Sweden.
  • Puhl AC; Collaborations Pharmaceuticals, 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
  • Andrade CH; LabMol - Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil; Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP 13083-864, Brazil. Electronic add
Drug Discov Today ; 25(5): 928-941, 2020 05.
Article in English | MEDLINE | ID: covidwho-72302
ABSTRACT
In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of déjà vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Drug Discovery / Betacoronavirus Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: Drug Discov Today Journal subject: Pharmacology / Drug Therapy Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Drug Discovery / Betacoronavirus Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: Drug Discov Today Journal subject: Pharmacology / Drug Therapy Year: 2020 Document Type: Article